Abstract

Counterfeiting medicines is a global phenomenon affecting developed and less developed countries. The World Health Organization, in its report, describes counterfeit medicines as becoming “a global public health crisis. This study examines consumers, stakeholders, and policymakers' perceptions of NAFDAC anti-counterfeit technologies and interventions regarding counterfeit drugs in Nigeria. This study uses a qualitative research method to examine consumers, stakeholders, and policymakers' perceptions of NAFDAC anti-counterfeit technologies and interventions regarding counterfeit drugs in Nigeria. Participants were selected using convenience sampling, and data was collected through an online interview. Data were analysed using thematic analysis. Stakeholders emphasised the importance of NAFDAC having a comprehensive anti-counterfeiting strategy and implementing measures such as checking for NAFDAC registration numbers, inspecting packaging, and requesting seller receipts to identify genuine medicines. Policymakers at NAFDAC acknowledge the seriousness of the problem and recognise the roles of stakeholders in implementing anti-counterfeiting interventions. They emphasise the need for effective communication, engagement, and collaboration with healthcare professionals. Consumers express concerns about the accessibility to good quality medicines and the prevalence of substandard and counterfeit drugs. However, consumers also demonstrate a willingness to support NAFDAC's efforts and show a preference for quality medicines, which is a positive indicator for the Nigerian pharmaceutical industry. The findings underscore the importance of continuous efforts to raise awareness and implement effective anti-counterfeiting strategies to safeguard public health and combat the growing threat of fake drugs. Keywords: Falsified, Substandard, Counterfeit, Knowledge.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call